Dominic joined Advent Life Sciences in April 2022, bringing a rich background in biochemistry, genomics, molecular oncology, strategy consulting, and life science venture capital.

Before joining Advent, he dedicated eight years as a Partner in the investment team of Syncona, a publicly listed healthcare investment company. Dominic played a pivotal role in the founding, funding, and growth of several life science businesses. He served on the Boards of multiple preclinical and clinical stage biotech companies, including Orbit Biomedical (merged with Gyroscope) and Gyroscope Therapeutics (acquired by Novartis for up to $1.5 billion).

Dominic earned a German Diplom Degree in Biochemistry from the Free University of Berlin and the Max Planck Institute for Molecular Genetics. Subsequently, he attained a PhD from the Department of Oncology at the University of Cambridge. His doctoral research, supported by a Cancer Research UK scholarship, resulted in publications in eminent journals including Cell, Nature, and Science. Dominic’s outstanding contributions were acknowledged with prestigious awards, namely the Pontecorvo and Science & SciLife Lab Prizes.

Back to Team